Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients

Dora Larussa, Patrizia Lorenzini, Antonella Cingolani, Simona Bossolasco, Susanna Grisetti, Marco Bongiovanni, Francesca Moretti, Ilaria Uccella, Paolo Zannoni, Sergio Foresti, Giovanni Mazzarello, Maria Irene Arcidiacono, Rosa Pedale, Adriana Ammassari, Valerio Tozzi, Carlo Federico Perno, Antonella D Arminio Monforte, Paola Cinque, Andrea Antinori

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Historically, older patients have shown a higher risk of HIV-1-associated dementia (HIVD). The objective of this study was to evaluate the association of aging with HIVD and minor cognitive motor disorders (MCMDs) during the late-highly active antiretroviral therapy (HAART) era and to analyze characteristics, predictive factors, and survival of older HIV-1-infected individuals affected by these disorders. A nested longitudinal study was designed for a cohort of HIV-1-infected individuals with neurological diseases. Multiple logistic regression and Cox regression for survival were employed. From 2000 to 2003, 195 patients with HIVD (53%) or MCMD (47%) were enrolled. The cumulative prevalence of these two disorders was 21%, with an increasing rate for calendar year (p <0.001). Previous antiretroviral exposure occurred in 46% of patients. Mean CD4+ cell count and plasma HIV-1 RNA were 144 cells/μl and 4.5 log10 copies/ml, respectively. The mean age was 44 years (SD, 9.9), with 35% of patients aged 20-39 years (I), 45% aged 40-49 years (II), and 20% aged ≥50 years (III). Among drug-naive patients, the prevalence of HIVD progressively increased in older subjects: 7.2% (I), 15.3% (II), and 27.3% (III) (p <0.001), whereas no significant increase in HIVD with older age was observed in drug-treated subjects. Older age was independently associated with an increased risk of HIVD (odds ratio, 6.44; 95% confidence interval, 2.82-14.69) in naive but not in experienced individuals, but had no significant effect on survival. No significant effect of age was observed for MCMD. We conclude that in our cohort, HAART seems to alter the relationship between aging and HIVD, conferring a neuroprotective effect to older patients. These results may have significant implications for the clinical management of the older HIV population.

Original languageEnglish
Pages (from-to)386-392
Number of pages7
JournalAIDS Research and Human Retroviruses
Volume22
Issue number5
DOIs
Publication statusPublished - May 2006

Fingerprint

Highly Active Antiretroviral Therapy
Dementia
HIV-1
Survival
Neuroprotective Agents
CD4 Lymphocyte Count
Pharmaceutical Preparations
Longitudinal Studies
Logistic Models
Odds Ratio
HIV
RNA
Confidence Intervals

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients. / Larussa, Dora; Lorenzini, Patrizia; Cingolani, Antonella; Bossolasco, Simona; Grisetti, Susanna; Bongiovanni, Marco; Moretti, Francesca; Uccella, Ilaria; Zannoni, Paolo; Foresti, Sergio; Mazzarello, Giovanni; Arcidiacono, Maria Irene; Pedale, Rosa; Ammassari, Adriana; Tozzi, Valerio; Perno, Carlo Federico; Monforte, Antonella D Arminio; Cinque, Paola; Antinori, Andrea.

In: AIDS Research and Human Retroviruses, Vol. 22, No. 5, 05.2006, p. 386-392.

Research output: Contribution to journalArticle

Larussa, D, Lorenzini, P, Cingolani, A, Bossolasco, S, Grisetti, S, Bongiovanni, M, Moretti, F, Uccella, I, Zannoni, P, Foresti, S, Mazzarello, G, Arcidiacono, MI, Pedale, R, Ammassari, A, Tozzi, V, Perno, CF, Monforte, ADA, Cinque, P & Antinori, A 2006, 'Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients', AIDS Research and Human Retroviruses, vol. 22, no. 5, pp. 386-392. https://doi.org/10.1089/aid.2006.22.386
Larussa, Dora ; Lorenzini, Patrizia ; Cingolani, Antonella ; Bossolasco, Simona ; Grisetti, Susanna ; Bongiovanni, Marco ; Moretti, Francesca ; Uccella, Ilaria ; Zannoni, Paolo ; Foresti, Sergio ; Mazzarello, Giovanni ; Arcidiacono, Maria Irene ; Pedale, Rosa ; Ammassari, Adriana ; Tozzi, Valerio ; Perno, Carlo Federico ; Monforte, Antonella D Arminio ; Cinque, Paola ; Antinori, Andrea. / Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients. In: AIDS Research and Human Retroviruses. 2006 ; Vol. 22, No. 5. pp. 386-392.
@article{36c14dcf72be4543a14f93f31d809108,
title = "Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients",
abstract = "Historically, older patients have shown a higher risk of HIV-1-associated dementia (HIVD). The objective of this study was to evaluate the association of aging with HIVD and minor cognitive motor disorders (MCMDs) during the late-highly active antiretroviral therapy (HAART) era and to analyze characteristics, predictive factors, and survival of older HIV-1-infected individuals affected by these disorders. A nested longitudinal study was designed for a cohort of HIV-1-infected individuals with neurological diseases. Multiple logistic regression and Cox regression for survival were employed. From 2000 to 2003, 195 patients with HIVD (53{\%}) or MCMD (47{\%}) were enrolled. The cumulative prevalence of these two disorders was 21{\%}, with an increasing rate for calendar year (p <0.001). Previous antiretroviral exposure occurred in 46{\%} of patients. Mean CD4+ cell count and plasma HIV-1 RNA were 144 cells/μl and 4.5 log10 copies/ml, respectively. The mean age was 44 years (SD, 9.9), with 35{\%} of patients aged 20-39 years (I), 45{\%} aged 40-49 years (II), and 20{\%} aged ≥50 years (III). Among drug-naive patients, the prevalence of HIVD progressively increased in older subjects: 7.2{\%} (I), 15.3{\%} (II), and 27.3{\%} (III) (p <0.001), whereas no significant increase in HIVD with older age was observed in drug-treated subjects. Older age was independently associated with an increased risk of HIVD (odds ratio, 6.44; 95{\%} confidence interval, 2.82-14.69) in naive but not in experienced individuals, but had no significant effect on survival. No significant effect of age was observed for MCMD. We conclude that in our cohort, HAART seems to alter the relationship between aging and HIVD, conferring a neuroprotective effect to older patients. These results may have significant implications for the clinical management of the older HIV population.",
author = "Dora Larussa and Patrizia Lorenzini and Antonella Cingolani and Simona Bossolasco and Susanna Grisetti and Marco Bongiovanni and Francesca Moretti and Ilaria Uccella and Paolo Zannoni and Sergio Foresti and Giovanni Mazzarello and Arcidiacono, {Maria Irene} and Rosa Pedale and Adriana Ammassari and Valerio Tozzi and Perno, {Carlo Federico} and Monforte, {Antonella D Arminio} and Paola Cinque and Andrea Antinori",
year = "2006",
month = "5",
doi = "10.1089/aid.2006.22.386",
language = "English",
volume = "22",
pages = "386--392",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Highly active antiretroviral therapy reduces the age-associated risk of dementia in a cohort of older HIV-1-infected patients

AU - Larussa, Dora

AU - Lorenzini, Patrizia

AU - Cingolani, Antonella

AU - Bossolasco, Simona

AU - Grisetti, Susanna

AU - Bongiovanni, Marco

AU - Moretti, Francesca

AU - Uccella, Ilaria

AU - Zannoni, Paolo

AU - Foresti, Sergio

AU - Mazzarello, Giovanni

AU - Arcidiacono, Maria Irene

AU - Pedale, Rosa

AU - Ammassari, Adriana

AU - Tozzi, Valerio

AU - Perno, Carlo Federico

AU - Monforte, Antonella D Arminio

AU - Cinque, Paola

AU - Antinori, Andrea

PY - 2006/5

Y1 - 2006/5

N2 - Historically, older patients have shown a higher risk of HIV-1-associated dementia (HIVD). The objective of this study was to evaluate the association of aging with HIVD and minor cognitive motor disorders (MCMDs) during the late-highly active antiretroviral therapy (HAART) era and to analyze characteristics, predictive factors, and survival of older HIV-1-infected individuals affected by these disorders. A nested longitudinal study was designed for a cohort of HIV-1-infected individuals with neurological diseases. Multiple logistic regression and Cox regression for survival were employed. From 2000 to 2003, 195 patients with HIVD (53%) or MCMD (47%) were enrolled. The cumulative prevalence of these two disorders was 21%, with an increasing rate for calendar year (p <0.001). Previous antiretroviral exposure occurred in 46% of patients. Mean CD4+ cell count and plasma HIV-1 RNA were 144 cells/μl and 4.5 log10 copies/ml, respectively. The mean age was 44 years (SD, 9.9), with 35% of patients aged 20-39 years (I), 45% aged 40-49 years (II), and 20% aged ≥50 years (III). Among drug-naive patients, the prevalence of HIVD progressively increased in older subjects: 7.2% (I), 15.3% (II), and 27.3% (III) (p <0.001), whereas no significant increase in HIVD with older age was observed in drug-treated subjects. Older age was independently associated with an increased risk of HIVD (odds ratio, 6.44; 95% confidence interval, 2.82-14.69) in naive but not in experienced individuals, but had no significant effect on survival. No significant effect of age was observed for MCMD. We conclude that in our cohort, HAART seems to alter the relationship between aging and HIVD, conferring a neuroprotective effect to older patients. These results may have significant implications for the clinical management of the older HIV population.

AB - Historically, older patients have shown a higher risk of HIV-1-associated dementia (HIVD). The objective of this study was to evaluate the association of aging with HIVD and minor cognitive motor disorders (MCMDs) during the late-highly active antiretroviral therapy (HAART) era and to analyze characteristics, predictive factors, and survival of older HIV-1-infected individuals affected by these disorders. A nested longitudinal study was designed for a cohort of HIV-1-infected individuals with neurological diseases. Multiple logistic regression and Cox regression for survival were employed. From 2000 to 2003, 195 patients with HIVD (53%) or MCMD (47%) were enrolled. The cumulative prevalence of these two disorders was 21%, with an increasing rate for calendar year (p <0.001). Previous antiretroviral exposure occurred in 46% of patients. Mean CD4+ cell count and plasma HIV-1 RNA were 144 cells/μl and 4.5 log10 copies/ml, respectively. The mean age was 44 years (SD, 9.9), with 35% of patients aged 20-39 years (I), 45% aged 40-49 years (II), and 20% aged ≥50 years (III). Among drug-naive patients, the prevalence of HIVD progressively increased in older subjects: 7.2% (I), 15.3% (II), and 27.3% (III) (p <0.001), whereas no significant increase in HIVD with older age was observed in drug-treated subjects. Older age was independently associated with an increased risk of HIVD (odds ratio, 6.44; 95% confidence interval, 2.82-14.69) in naive but not in experienced individuals, but had no significant effect on survival. No significant effect of age was observed for MCMD. We conclude that in our cohort, HAART seems to alter the relationship between aging and HIVD, conferring a neuroprotective effect to older patients. These results may have significant implications for the clinical management of the older HIV population.

UR - http://www.scopus.com/inward/record.url?scp=33646878513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646878513&partnerID=8YFLogxK

U2 - 10.1089/aid.2006.22.386

DO - 10.1089/aid.2006.22.386

M3 - Article

VL - 22

SP - 386

EP - 392

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 5

ER -